Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632245 | 0.81 | ADAM17 (0.63) | CYP1A2ADAM17MMP13SMN1; SMN2HTT | |
| SCHEMBL265139 | 0.80 | NCF1 (0.61) | NCF1CYP1A2SMN1; SMN2HTTKDM4E | |
| SCHEMBL14075461 | 0.79 | CYP1A2 (0.50) | NCF1CYP1A2ADAM17MMP13SMN1; SMN2 | |
| SCHEMBL28286574 | 0.79 | CYP1A2 (0.50) | NCF1CYP1A2ADAM17MMP13SMN1; SMN2 | |
| SCHEMBL1364646 | 0.79 | ADAM17 (0.60) | NCF1ADAM17MMP13MMP2 | |
| SCHEMBL8232676 | 0.78 | CYP1A2 (0.62) | NCF1CYP1A2SMN1; SMN2HTTMEN1 | |
| SCHEMBL1366357 | 0.78 | CYP1A2 (0.62) | NCF1CYP1A2SMN1; SMN2HTTMEN1 | |
| SCHEMBL15677596 | 0.78 | CYP1A2 (0.49) | NCF1CYP1A2ADAM17MMP13SMN1; SMN2 | |
| SCHEMBL5935677 | 0.78 | CYP1A2 (0.49) | NCF1CYP1A2ADAM17MMP13SMN1; SMN2 | |
| SCHEMBL6633551 | 0.78 | RAB9A (0.53) | NCF1CYP1A2ADAM17MMP13SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | NCF1 2462/4885CYP1A2 45/4885ADAM17 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.